

# Francesco Franchi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1678711/publications.pdf>

Version: 2024-02-01

75  
papers

3,407  
citations

186265

28  
h-index

144013

57  
g-index

78  
all docs

78  
docs citations

78  
times ranked

3521  
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y <sub>12</sub> Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2019, 12, 1521-1537.	2.9	366
2	Novel antiplatelet agents in acute coronary syndrome. Nature Reviews Cardiology, 2015, 12, 30-47.	13.7	299
3	International Expert Consensus on Switching Platelet P2Y <sub>12</sub> Receptor Inhibiting Therapies. Circulation, 2017, 136, 1955-1975.	1.6	293
4	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nature Reviews Cardiology, 2018, 15, 480-496.	13.7	180
5	Impaired Responsiveness to the Platelet P2Y <sub>12</sub> Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease. Journal of the American College of Cardiology, 2014, 64, 1005-1014.	2.8	155
6	Switching P2Y <sub>12</sub> -receptor inhibitors in patients with coronary artery disease. Nature Reviews Cardiology, 2016, 13, 11-27.	13.7	154
7	Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet, The, 2021, 397, 1470-1483.	13.7	133
8	Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. Journal of the American College of Cardiology, 2016, 67, 1145-1154.	2.8	108
9	Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation, 2019, 139, 1661-1670.	1.6	106
10	Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2016, 67, 1994-2004.	2.8	104
11	Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy. Clinical Pharmacology and Therapeutics, 2018, 104, 664-674.	4.7	94
12	Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation, 2016, 134, 780-792.	1.6	82
13	Comparative effects of guided vs. potent P2Y <sub>12</sub> inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. European Heart Journal, 2022, 43, 959-967.	2.2	79
14	Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nature Reviews Cardiology, 2017, 14, 361-379.	13.7	76
15	Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2015, 8, 1457-1467.	2.9	71
16	Institutional profile: University of Florida Health Personalized Medicine Program. Pharmacogenomics, 2017, 18, 421-426.	1.3	64
17	Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy. Progress in Cardiovascular Diseases, 2018, 60, 478-490.	3.1	61
18	Role of genetic testing in patients undergoing percutaneous coronary intervention. Expert Review of Clinical Pharmacology, 2018, 11, 151-164.	3.1	57

#	ARTICLE	IF	CITATIONS
19	Cangrelor: a review on pharmacology and clinical trial development. Expert Review of Cardiovascular Therapy, 2013, 11, 1279-1291.	1.5	52
20	A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. European Heart Journal, 2016, 37, 2722-2730.	2.2	52
21	Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease. Circulation, 2018, 137, 2450-2462.	1.6	46
22	Diabetes and antiplatelet therapy: from bench to bedside. Cardiovascular Diagnosis and Therapy, 2018, 8, 594-609.	1.7	45
23	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 677-686.	3.0	45
24	Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI. Journal of the American College of Cardiology, 2016, 67, 603-613.	2.8	41
25	Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. Journal of Translational Medicine, 2018, 16, 92.	4.4	41
26	Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor. JACC: Cardiovascular Interventions, 2016, 9, 1089-1098.	2.9	35
27	Platelet Function Testing in Contemporary Clinical and Interventional Practice. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 300.	0.9	34
28	Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y <sub>12</sub> Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial. Journal of the American Heart Association, 2019, 8, e011139.	3.7	33
29	Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. Journal of the American Heart Association, 2017, 6, .	3.7	30
30	Pharmacodynamic Effects of Cangrelor on Platelet P2Y <sub>12</sub> Receptor-Mediated Signaling in Prasugrel-Treated Patients. JACC: Cardiovascular Interventions, 2014, 7, 426-434.	2.9	28
31	Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. Expert Review of Clinical Pharmacology, 2021, 14, 963-978.	3.1	27
32	Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine. JACC: Cardiovascular Interventions, 2019, 12, 1538-1549.	2.9	26
33	Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Clinical Pharmacology and Therapeutics, 2021, 109, 705-715.	4.7	25
34	Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike. Progress in Cardiovascular Diseases, 2015, 58, 267-277.	3.1	22
35	Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study. Thrombosis and Haemostasis, 2020, 120, 083-093.	3.4	21
36	Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention. Trends in Cardiovascular Medicine, 2023, 33, 133-138.	4.9	21

#	ARTICLE	IF	CITATIONS
37	Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes. JACC Basic To Translational Science, 2020, 5, 419-428.	4.1	18
38	Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development. Future Cardiology, 2015, 11, 547-564.	1.2	17
39	Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 23-37.	2.0	17
40	The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts. Expert Review of Hematology, 2018, 11, 5-12.	2.2	17
41	Role of thromboelastography and rapid thromboelastography to assess the pharmacodynamic effects of vitamin K antagonists. Journal of Thrombosis and Thrombolysis, 2015, 40, 118-125.	2.1	15
42	Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study. BMJ Open Diabetes Research and Care, 2021, 9, e001939.	2.8	15
43	&lt;p&gt;Development of Customizable Implementation Guides to Support Clinical Adoption of Pharmacogenomics: Experiences of the Implementing GeNomics In pracTicE (IGNITE) Network&lt;/p&gt;. Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 217-226.	0.7	14
44	A Safety Evaluation of Cangrelor in Patients Undergoing PCI. Expert Opinion on Drug Safety, 2016, 15, 275-285.	2.4	12
45	Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus. JACC Basic To Translational Science, 2019, 4, 763-775.	4.1	12
46	Defining the Link Between Chronic Kidney Disease, High Platelet Reactivity, and Clinical Outcomes in Clopidogrel-Treated Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2015, 8, e002760.	3.9	11
47	Switching P2Y12 Receptor Inhibiting Therapies. Interventional Cardiology Clinics, 2017, 6, 67-89.	0.4	10
48	Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention. Circulation, 2020, 142, 1500-1502.	1.6	10
49	Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor. Journal of Thrombosis and Thrombolysis, 2021, 51, 741-747.	2.1	10
50	Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention. Clinical and Translational Science, 2020, 13, 473-481.	3.1	9
51	Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection. Genetics in Medicine, 2020, 22, 1898-1902.	2.4	9
52	Perspectives on the management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery. Current Opinion in Cardiology, 2014, 29, 553-563.	1.8	8
53	Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors. Thrombosis and Haemostasis, 2016, 116, 1060-1069.	3.4	8
54	In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor-Mediated Signaling in Ticagrelor-Treated Patients. JACC: Cardiovascular Interventions, 2017, 10, 1374-1375.	2.9	8

#	ARTICLE	IF	CITATIONS
55	The Quest for the Optimal Periprocedural Antithrombotic Treatment Strategy in ACS Patients Undergoing PCI. Journal of the American College of Cardiology, 2018, 71, 1243-1245.	2.8	8
56	Clopidogrel drug interactions: a review of the evidence and clinical implications. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 1079-1096.	3.3	8
57	Drug-Drug Interactions When Switching Between Intravenous and Oral P2Y12 Receptor Inhibitors. JACC: Cardiovascular Interventions, 2017, 10, 130-132.	2.9	7
58	Guided selection of antiplatelet therapy in acute coronary syndrome: Impact on outcomes and resource utilization. International Journal of Cardiology, 2021, 345, 36-38.	1.7	7
59	Impact of the ABCD GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation. Clinical Pharmacology and Therapeutics, 2022, 112, 146-155.	4.7	7
60	Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 728-737.	3.0	6
61	Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy. JACC: Cardiovascular Interventions, 2015, 8, 1075-1083.	2.9	5
62	De-Escalation of Platelet P2Y12 Receptor Inhibiting Therapy After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2017, 10, 2571-2573.	2.9	5
63	Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease. Thrombosis and Haemostasis, 2022, 122, 1341-1351.	3.4	5
64	Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction. Trends in Cardiovascular Medicine, 2016, 26, 321-334.	4.9	3
65	Switching from ticagrelor to clopidogrel: New answers and further questions. Thrombosis and Haemostasis, 2017, 117, 207-208.	3.4	3
66	Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations. Therapeutic Advances in Hematology, 2019, 10, 204062071986147.	2.5	3
67	Patterns and Outcomes of Dual Antiplatelet Therapy Discontinuation After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2022, 15, 807-809.	2.9	3
68	Standard- and Low-Dose Ticagrelor After Percutaneous Coronary Intervention. Circulation, 2018, 138, 1301-1303.	1.6	2
69	Genotype-Guided Antiplatelet Therapy in Patients With Coronary Artery Disease. JACC: Cardiovascular Interventions, 2021, 14, 751-753.	2.9	2
70	Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 452-461.	3.0	2
71	Defining a Role for Prasugrel in Patients With Stable Coronary Artery Disease Undergoing Ad Hoc Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 228-230.	2.9	1
72	Switching Oral Anticoagulant Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2019, 12, 2342-2345.	2.9	1

#	ARTICLE	IF	CITATIONS
73	Abstract 16668: The Effects of Dabigatran on Fibrin Network Structure and Lysis: A Simple Technique to Monitor Efficacy of Treatment?. Circulation, 2014, 130, .	1.6	0
74	Typical atrial flutter from blunt cardiac injury: an atypical cause. Journal of Geriatric Cardiology, 2021, 18, 155-157.	0.2	0
75	10â€ŒPharmacodynamic profiles of aspirin versus dual-pathway inhibition with either aspirin or clopidogrel among patients with stable atherosclerotic disease. European Heart Journal Supplements, 2021, 23, .	0.1	0